Most early fibrosis responses to efruxifermin held through 96 weeks in phase 2b trials

Share

Most patients with metabolic dysfunction-associated steatohepatitis (MASH) who had an early fibrosis response to efruxifermin kept that response through 96 weeks, and others responded for the first time by week 96, according to an analysis of two phase 2b trials presented at the American College of Gastroenterology’s 2026 Annual Scientific Meeting in Nashville, Tennessee.

Arun J. Sanyal, MD, of Virginia Commonwealth University in Richmond, presented the findings on efruxifermin, an investigational fibroblast growth factor 21 (FGF21) analog.

There are no approved treatments for MASH cirrhosis, Dr. Sanyal said during his presentation. “The aim of this particular project was to actually evaluate the time course of fibrosis improvement in these trials,” he said.

Assessing long-term fibrosis improvement

The two trials — HARMONY and SYMMETRY — were randomized, double-blind, placebo-controlled phase 2b trials involving 126 participants with moderate to advanced liver fibrosis (F2/F3) and 181 with compensated cirrhosis (F4), respectively. Participants received once-weekly placebo or efruxifermin 28 mg or 50 mg, with liver biopsies at baseline, week 24 (HARMONY) or week 36 (SYMMETRY), and week 96. Fibrosis response was defined as at least one-stage fibrosis improvement without MASH worsening.

The analysis included 88 HARMONY and 134 SYMMETRY participants with week-96 biopsies. It was presented as an abstract and has not been published in a peer-reviewed journal; primary 96-week results were published in 2025 in The Lancet and The New England Journal of Medicine, respectively.

In HARMONY, 75% of participants receiving 50 mg had a fibrosis response at week 96, compared with 46% with 28 mg and 24% with placebo (P < .001 for 50 mg; 28 mg was not significant). “Even though the numbers are relatively small, three out of four patients actually reversed their fibrosis stage with blinded histology assessment,” Dr. Sanyal said. MASH resolution occurred in 57% to 62% of efruxifermin recipients vs. 24% with placebo.

In the 50-mg group, 11 of 12 week-24 responders maintained their response at week 96, and 10 more responded for the first time at week 96. “It showed that with continued therapy, you had incremental gain in fibrosis benefit,” he said.

In SYMMETRY, 39% of participants receiving 50 mg had a fibrosis response at week 96, compared with 29% with 28 mg and 15% with placebo (P < .01 for 50 mg; 28 mg was not significant). At week 36, the differences were not statistically significant (24% with 50 mg vs. 14% with placebo), according to the abstract. In the 50-mg group, nine of 12 week-36 responders maintained their response, and nine more responded at week 96.

Late responses also occurred with placebo. Asked whether they reflected true late response or biopsy sampling error, Dr. Sanyal said “the numbers are just too small to make any kind of conclusion.”

Liver stiffness improved progressively in both populations, Dr. Sanyal said. The improvement with 50 mg was statistically significant at week 96 in both trials, and Enhanced Liver Fibrosis scores improved with both doses, according to the abstract.

Safety and future research

The most common adverse events were gastrointestinal and “by and large mild to moderate and transient,” Dr. Sanyal said. FGF21 analogs also “increased appetite and increased desire for savory foods,” he said, though mean body weight was generally unchanged.

In SYMMETRY, adverse events led to discontinuation in 17% of the 50-mg group, 11% of the 28-mg group, and 3% of the placebo group (HARMONY: 7%, 10%, and 0%). Serious adverse events occurred in 24%, 26%, and 18%, respectively (HARMONY: 9%, 0%, and 0%). No drug-induced liver injury was reported.

Bone mineral density decreased slightly but significantly at week 96, with no increase in fractures. Dr. Sanyal said the decrease will be “watched very carefully” in phase 3 because many patients with cirrhosis are older.

He described the trials’ sample sizes as typical for phase 2b, and the analysis was limited to participants who agreed to a week-96 biopsy.

Two ongoing phase 3 studies, SYNCHRONY Histology (NCT06215716) and SYNCHRONY Outcomes (NCT06528314), are evaluating efruxifermin in patients with MASH-related fibrosis and compensated cirrhosis.

Dr. Sanyal reported consulting for and receiving research support from Akero Therapeutics and Novo Nordisk, among other companies. Three coauthors are employees of Akero Therapeutics, a Novo Nordisk company; the others reported relationships with Akero and other companies.